Vascular Calcification Mechanisms in Chronic Kidney Disease

Chronic kidney disease (CKD) disrupts mineral homeostasis, leading to the pathological deposition of calcium phosphate crystals within the arterial wall. Medial vascular calcification, which predominates in CKD, arises from a complex interplay of hyperphosphataemia, uraemic toxins, oxidative stress and chronic inflammation. Under these conditions, vascular smooth muscle cells (VSMCs) undergo phenotypic switching towards osteogenic lineages, secreting matrix vesicles and extracellular matrix proteins that nucleate mineral deposition. Concurrently, levels of endogenous inhibitors such as fetuin-A and matrix Gla protein are reduced, further permitting crystal growth. Key signalling cascades implicated include Wnt/β-catenin, bone morphogenetic protein (BMP), AKT and NF-κB pathways, as well as DNA repair enzymes such as poly(ADP-ribose) polymerase 1 (PARP1). The resultant calcified arterial segments exhibit increased stiffness, accelerated pulse-wave velocity and a markedly higher risk of cardiovascular events. Globally, vascular calcification in CKD patients drives morbidity and mortality, prompting development of phosphate binders, vitamin K supplementation and targeted molecular therapies to halt or reverse the process.

Research from Nature Portfolio

Recent studies have identified PARP1 as a pivotal regulator of VSMC osteogenic transdifferentiation in uraemic environments. Elevated PARP1 activity was observed in arterial specimens from renal failure patients, in uraemic rodent models and in calcified VSMC cultures. Genetic deletion or pharmacological inhibition of PARP1 attenuated calcium deposition by suppressing the IL-6/STAT3 pathway, restoring microRNA-204 levels and thereby decreasing expression of the master osteogenic transcription factor Runx2. These findings position PARP1 as a promising therapeutic target to mitigate vascular calcification in CKD.

Vascular Calcification Mechanisms in Chronic Kidney Disease publication trend

The graph below shows the total number of articles in vascular calcification mechanisms in chronic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Vascular calcification: Pathological deposition of calcium phosphate crystals within the vascular wall.

Vascular smooth muscle cell (VSMC): Principal medial arterial wall cell capable of phenotypic switching.

Osteogenic transdifferentiation: Process by which VSMCs adopt bone-forming cell characteristics.

Hyperphosphataemia: Elevated serum phosphate concentration common in CKD.

Poly(ADP-ribose) polymerase 1 (PARP1): DNA repair enzyme that modulates inflammatory signalling and Runx2 expression.

Runx2: Master transcription factor driving osteoblast-like gene programmes in VSMCs.

Extracellular vesicle: Membrane-bound particle secreted by cells, here used for targeted drug delivery.

Sodium thiosulphate (STS): Calcium-chelating drug repurposed to inhibit vascular calcification.

References

1. Biomimetic Grapefruit-Derived Extracellular Vesicles for Safe and Targeted Delivery of Sodium Thiosulfate against Vascular Calcification. ACS Nano (2023).
2. Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia. Cellular and Molecular Life Sciences (2019).
3. SGK1 induces vascular smooth muscle cell calcification through NF-κB signaling. Journal of Clinical Investigation (2018).
4. Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2. Nature Communications (2019).
5. Oxidative Stress Induces Vascular Calcification through Modulation of the Osteogenic Transcription Factor Runx2 by AKT Signaling*. Journal of Biological Chemistry (2008).
6. The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. Journal of Clinical Investigation (2003).
7. BMP signaling in vascular diseases. FEBS Letters (2012).